Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Peanut Allergy Treatment Market

Peanut Allergy Treatment Market Trends

Report ID: GMI10199
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Peanut Allergy Treatment Market Trends

Epicutaneous immunotherapy is an emerging treatment option for peanut allergies, specifically among pediatric patients. Products such as Viaskin peanut patch has shown promising potential in desensitizing many peanut-allergic pediatric patients. This desensitization helps in lowering the risk of allergic reactions from accidental exposure to peanut. Vendors are increasingly exploring potentials of epicutaneous immunotherapy which is expected to offer lucrative growth opportunities during the forecast period.
Moreover, increasing investments by vendors have resulted in the existence of robust pipeline of potential candidates of immunotherapy drugs such as ADP101, PVX108, VE416, INP20. Owing to their high potential of success, these products are securing significant investments for clinical developments. For instance, in December 2022, Aravax Pty Ltd initiated its series B funding round, through securing an investment of ~USD 22 million to commence phase II clinical trials for PVX108, a promising candidate for treating peanut allergies.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Peanut allergy treatment industry size was worth USD 483.5 million in 2023 and is projected to expand at 12.1% CAGR from 2024 to 2032, due to growing prevalence of peanut allergies, and increasing investments for developing new treatment modalities.

The injectable route of administration segment in the peanut allergy treatment industry accounted for 51.4% share in 2023 as they find extensive use in delivering epinephrine and immunotherapeutic treatments such as Dupixent.

The epinephrine drug class segment in the peanut allergy treatment industry accounted for USD 233 million in 2023 owing to drug ability to reverse any life-threatening symptoms such as swelling of the airway and low blood pressure.

North America peanut allergy treatment industry accounted for 41.3% share in 2023 and is projected to expand at substantial rate from 2024 to 2032, led by the increasing prevalence of peanut allergies in the region.